ResMed (RMD) Stock Forecast, Price Target & Predictions
RMD Stock Forecast
ResMed stock forecast is as follows: an average price target of $219.13 (represents a -8.47% downside from RMD’s last price of $239.42) and a rating consensus of 'Hold', based on 22 wall street analysts offering a 1-year stock forecast.
RMD Price Target
The average price target for ResMed (RMD) is $219.13 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $280.00 to $175.00. This represents a potential -8.47% downside from RMD's last price of $239.42.
RMD Analyst Ratings
According to 22 Wall Street analysts, ResMed's rating consensus is 'Hold'. The analyst rating breakdown for RMD stock is 0 'Strong Buy' (0.00%), 9 'Buy' (40.91%), 12 'Hold' (54.55%), 1 'Sell' (4.55%), and 0 'Strong Sell' (0.00%).
ResMed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 01, 2024 | Craig Wong-Pan | RBC Capital | $224.00 | $238.95 | -6.26% | -6.44% |
| Sep 23, 2024 | Joe Vruwink | Robert W. Baird | $280.00 | $246.18 | 13.74% | 16.95% |
| Sep 18, 2024 | Mike Polark | Wolfe Research | $180.00 | $250.88 | -28.25% | -24.82% |
| Apr 10, 2024 | Craig Wong-Pan | RBC Capital | $187.00 | $194.27 | -3.74% | -21.89% |
| Apr 01, 2024 | Mike Matson | Stifel Nicolaus | $224.00 | $198.03 | 13.11% | -6.44% |
| Oct 27, 2023 | Suraj Kalia | Oppenheimer | $175.00 | $134.65 | 29.97% | -26.91% |
| Sep 06, 2023 | Mike Matson | Needham | $180.00 | $153.89 | 16.97% | -24.82% |
| Jun 20, 2022 | Craig Wong-Pan | RBC Capital | $244.00 | $197.57 | 23.50% | 1.91% |
| Apr 29, 2022 | - | RBC Capital | $233.00 | $200.81 | 16.03% | -2.68% |
| Oct 14, 2021 | Suraj Kalia | Oppenheimer | $312.00 | $253.77 | 22.95% | 30.31% |
The latest ResMed stock forecast, released on Oct 01, 2024 by Craig Wong-Pan from RBC Capital, set a price target of $224.00, which represents a -6.26% decrease from the stock price at the time of the forecast ($238.95), and a -6.44% decrease from RMD last price ($239.42).
ResMed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 5 |
| Avg Price Target | - | $228.00 | $219.00 |
| Last Closing Price | $239.42 | $239.42 | $239.42 |
| Upside/Downside | -100.00% | -4.77% | -8.53% |
In the current month, the average price target of ResMed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ResMed's last price of $239.42. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 24, 2024 | Wolfe Research | Sector Perform | Sector Perform | Hold |
| Sep 18, 2024 | Needham | Hold | Hold | Hold |
| Sep 18, 2024 | Wolfe Research | Peer Perform | Underperform | Downgrade |
| Sep 04, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Sep 04, 2024 | Needham | Buy | Hold | Downgrade |
| Aug 27, 2024 | William Blair | Outperform | Outperform | Hold |
| Aug 02, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Jul 23, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 25, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
ResMed's last stock rating was published by RBC Capital on Oct 01, 2024. The company gave RMD a "Sector Perform" rating, the same as its previous rate.
ResMed Financial Forecast
ResMed Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.16B | - | $1.12B | $1.12B | $1.03B | $950.29M | $914.74M | $864.50M | $894.87M | $904.01M | $876.10M | $768.77M | $800.01M | $751.94M | $770.34M | $769.46M |
| Avg Forecast | $1.50B | $1.46B | $1.44B | $1.41B | $1.42B | $1.38B | $1.36B | $1.31B | $1.33B | $1.30B | $1.27B | $1.19B | $1.22B | $1.17B | $1.15B | $1.10B | $1.14B | $1.05B | $996.10M | $949.78M | $910.56M | $904.59M | $921.91M | $856.61M | $799.54M | $797.03M | $782.57M | $710.06M | $752.04M | $724.07M |
| High Forecast | $1.53B | $1.48B | $1.46B | $1.43B | $1.44B | $1.41B | $1.38B | $1.34B | $1.35B | $1.31B | $1.29B | $1.19B | $1.22B | $1.17B | $1.19B | $1.13B | $1.16B | $1.07B | $1.01B | $949.78M | $910.56M | $904.59M | $921.91M | $856.61M | $799.54M | $797.03M | $782.57M | $710.06M | $752.04M | $724.07M |
| Low Forecast | $1.49B | $1.44B | $1.42B | $1.39B | $1.40B | $1.37B | $1.34B | $1.30B | $1.31B | $1.29B | $1.26B | $1.18B | $1.22B | $1.17B | $1.13B | $1.06B | $1.13B | $1.04B | $984.96M | $949.78M | $910.56M | $904.59M | $921.91M | $856.61M | $799.54M | $797.03M | $782.57M | $710.06M | $752.04M | $724.07M |
| # Analysts | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 9 | 4 | 3 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 6 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | - | 0.98% | 1.06% | 1.04% | 1.00% | 1.00% | 0.96% | 0.97% | 1.06% | 1.10% | 0.96% | 1.02% | 1.06% | 1.02% | 1.06% |
ResMed's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.17B, with a low forecast of $1.17B, and a high forecast of $1.17B. RMD's average Quarter revenue forecast represents a 0.98% increase compared to the company's last Quarter revenue of $1.16B (Dec 23).
ResMed EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 9 | 4 | 3 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 6 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $275.09M | - | $333.76M | $347.04M | $342.56M | $319.77M | $300.40M | $285.87M | $280.94M | $306.41M | $290.24M | $271.76M | $264.58M | $272.58M | $266.80M | $248.09M |
| Avg Forecast | $502.23M | $488.21M | $481.58M | $470.52M | $473.27M | $461.98M | $453.38M | $438.92M | $443.31M | $433.47M | $424.22M | $396.08M | $407.16M | $367.05M | $384.44M | $368.74M | $381.52M | $333.68M | $325.96M | $318.22M | $305.08M | $303.35M | $308.89M | $287.01M | $267.88M | $265.35M | $262.20M | $237.91M | $251.97M | $191.38M |
| High Forecast | $510.50M | $496.25M | $489.51M | $478.27M | $481.06M | $469.59M | $460.85M | $446.15M | $450.61M | $436.86M | $431.21M | $396.81M | $407.16M | $440.46M | $397.70M | $377.15M | $387.81M | $400.42M | $391.15M | $318.22M | $305.08M | $364.02M | $308.89M | $287.01M | $267.88M | $318.41M | $262.20M | $237.91M | $251.97M | $229.66M |
| Low Forecast | $496.62M | $482.75M | $476.19M | $465.26M | $467.98M | $456.82M | $448.31M | $434.01M | $438.35M | $430.08M | $420.86M | $395.36M | $407.16M | $293.64M | $377.81M | $353.59M | $377.26M | $266.95M | $260.77M | $318.22M | $305.08M | $242.68M | $308.89M | $287.01M | $267.88M | $212.28M | $262.20M | $237.91M | $251.97M | $153.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | - | 0.87% | 1.04% | 1.05% | 1.00% | 0.98% | 0.94% | 0.91% | 1.07% | 1.08% | 1.02% | 1.01% | 1.15% | 1.06% | 1.30% |
3 analysts predict RMD's average Quarter EBITDA for Mar 24 to be $367.05M, with a high of $440.46M and a low of $293.64M. This is 33.43% upper than ResMed's previous annual EBITDA (Dec 23) of $275.09M.
ResMed Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 9 | 4 | 3 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 6 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $208.80M | - | $229.66M | $232.50M | $224.91M | $210.48M | $195.06M | $179.01M | $201.75M | $203.61M | $195.10M | $-78.48M | $179.51M | $178.37M | $177.84M | $163.14M |
| Avg Forecast | $423.51M | $407.82M | $400.81M | $382.13M | $387.59M | $381.26M | $372.45M | $355.14M | $363.30M | $353.91M | $342.35M | $303.19M | $307.41M | $231.86M | $262.16M | $238.98M | $247.84M | $210.78M | $229.23M | $226.46M | $212.72M | $191.62M | $220.69M | $202.40M | $190.87M | $-76.63M | $188.02M | $149.80M | $161.77M | $125.85M |
| High Forecast | $432.58M | $416.55M | $409.39M | $390.32M | $395.89M | $389.43M | $380.42M | $362.74M | $371.08M | $364.63M | $346.92M | $303.47M | $307.50M | $278.23M | $275.19M | $247.83M | $253.15M | $252.94M | $275.07M | $226.46M | $212.72M | $229.94M | $220.69M | $202.40M | $190.87M | $-61.30M | $188.02M | $149.80M | $161.77M | $151.02M |
| Low Forecast | $417.35M | $401.89M | $394.98M | $376.58M | $381.96M | $375.72M | $367.03M | $349.97M | $358.02M | $347.78M | $336.26M | $302.91M | $307.32M | $185.49M | $253.47M | $228.65M | $244.24M | $168.62M | $183.38M | $226.46M | $212.72M | $153.29M | $220.69M | $202.40M | $190.87M | $-91.95M | $188.02M | $149.80M | $161.77M | $100.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | - | 0.93% | 1.10% | 0.98% | 0.93% | 0.92% | 0.93% | 0.91% | 1.01% | 1.02% | 1.02% | 0.95% | 1.19% | 1.10% | 1.30% |
ResMed's average Quarter net income forecast for Mar 24 is $231.86M, with a range of $185.49M to $278.23M. RMD's average Quarter net income forecast represents a 11.04% increase compared to the company's last Quarter net income of $208.80M (Dec 23).
ResMed SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 9 | 4 | 3 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 6 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $222.16M | - | $240.69M | $228.46M | $211.67M | $193.93M | $194.89M | $182.40M | $185.36M | $176.72M | $181.48M | $160.45M | $169.47M | $158.99M | $165.38M | $172.44M |
| Avg Forecast | $314.96M | $306.17M | $302.01M | $295.08M | $296.80M | $289.72M | $284.33M | $275.26M | $278.01M | $271.84M | $266.04M | $248.39M | $255.34M | $236.25M | $241.09M | $231.25M | $239.26M | $214.77M | $210.61M | $199.05M | $190.83M | $195.25M | $193.21M | $179.53M | $167.57M | $156.66M | $164.01M | $148.81M | $157.61M | $133.03M |
| High Forecast | $320.15M | $311.21M | $306.98M | $299.94M | $301.69M | $294.49M | $289.01M | $279.79M | $282.59M | $273.97M | $270.42M | $248.85M | $255.34M | $283.50M | $249.41M | $236.52M | $243.20M | $257.72M | $252.73M | $199.05M | $190.83M | $234.30M | $193.21M | $179.53M | $167.57M | $187.99M | $164.01M | $148.81M | $157.61M | $159.63M |
| Low Forecast | $311.44M | $302.75M | $298.63M | $291.78M | $293.48M | $286.48M | $281.15M | $272.18M | $274.90M | $269.72M | $263.93M | $247.94M | $255.34M | $189.00M | $236.94M | $221.74M | $236.59M | $171.82M | $168.48M | $199.05M | $190.83M | $156.20M | $193.21M | $179.53M | $167.57M | $125.32M | $164.01M | $148.81M | $157.61M | $106.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | - | 1.01% | 1.06% | 1.01% | 0.97% | 1.02% | 0.93% | 0.96% | 0.98% | 1.08% | 1.02% | 1.03% | 1.07% | 1.05% | 1.30% |
ResMed's average Quarter SG&A projection for Mar 24 is $236.25M, based on 3 Wall Street analysts, with a range of $189.00M to $283.50M. The forecast indicates a 6.34% rise compared to RMD last annual SG&A of $222.16M (Dec 23).
ResMed EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 9 | 9 | 4 | 3 | 3 | 6 | 12 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 9 | 6 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.56 | $1.58 | $1.53 | $1.44 | $1.33 | $1.22 | $1.38 | $1.40 | $1.34 | $-0.54 | $1.24 | $1.23 | $1.23 | $1.13 |
| Avg Forecast | $2.87 | $2.76 | $2.72 | $2.59 | $2.63 | $2.58 | $2.52 | $2.41 | $2.46 | $2.40 | $2.32 | $2.05 | $2.08 | $1.93 | $1.78 | $1.62 | $1.68 | $1.61 | $1.61 | $1.53 | $1.44 | $1.46 | $1.50 | $1.37 | $1.29 | $1.29 | $1.27 | $1.02 | $1.10 | $1.03 |
| High Forecast | $2.93 | $2.82 | $2.77 | $2.64 | $2.68 | $2.64 | $2.58 | $2.46 | $2.51 | $2.47 | $2.35 | $2.06 | $2.08 | $1.93 | $1.86 | $1.68 | $1.72 | $1.64 | $1.65 | $1.53 | $1.44 | $1.47 | $1.50 | $1.37 | $1.29 | $1.29 | $1.27 | $1.02 | $1.10 | $1.03 |
| Low Forecast | $2.83 | $2.72 | $2.68 | $2.55 | $2.59 | $2.55 | $2.49 | $2.37 | $2.43 | $2.36 | $2.28 | $2.05 | $2.08 | $1.93 | $1.72 | $1.55 | $1.65 | $1.58 | $1.59 | $1.53 | $1.44 | $1.44 | $1.50 | $1.37 | $1.29 | $1.29 | $1.27 | $1.02 | $1.10 | $1.03 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.98% | 0.95% | 0.94% | 0.92% | 0.84% | 0.92% | 1.02% | 1.04% | -0.42% | 0.97% | 1.21% | 1.12% | 1.09% |
According to 12 Wall Street analysts, ResMed's projected average Quarter EPS for Sep 23 is $1.62, with a low estimate of $1.55 and a high estimate of $1.68. This represents a 3.79% increase compared to RMD previous annual EPS of $1.56 (Jun 23).
ResMed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $99.48 | $298.00 | 199.56% | Buy |
| STAA | STAAR Surgical Company | $26.38 | $54.58 | 106.90% | Buy |
| BAX | Baxter | $33.02 | $60.38 | 82.86% | Hold |
| TFX | Teleflex | $194.43 | $304.36 | 56.54% | Buy |
| BDX | Becton, Dickinson and Company | $224.10 | $283.27 | 26.40% | Buy |
| WST | West Pharmaceutical Services | $307.21 | $345.33 | 12.41% | Buy |
| ALC | Alcon | $85.81 | $93.89 | 9.42% | Buy |
| HOLX | Hologic | $78.79 | $80.21 | 1.80% | Buy |
| ICUI | ICU Medical | $169.98 | $172.00 | 1.19% | Buy |
| MMSI | Merit Medical Systems | $103.94 | $100.78 | -3.04% | Buy |
| RMD | ResMed | $239.42 | $219.13 | -8.47% | Hold |
| EMBC | Embecta | $14.42 | $12.00 | -16.78% | Sell |